CRL250516P85000
- 0.26
- +0.06+30.00%
Charles River Newsroom
Baird Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $118
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $105
BofA Securities Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $150
BofA Securities Cuts Charles River Laboratories International Price Target to $150 From $185
Baird Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $101
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $179
Charles River Labs Is Maintained at Equal-Weight by Barclays
Barclays Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $145
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $155
Mizuho Maintains Neutral on Charles River, Lowers Price Target to $155
Charles River Analyst Ratings
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating
Goldman Sachs Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $170
Charles River Analyst Ratings
Charles River Labs (CRL) Was Downgraded to a Hold Rating at Goldman Sachs
Citi Upgrades Charles River(CRL.US) to Hold Rating, Maintains Target Price $175
Charles River Labs Price Target Raised to $175.00/Share From $155.00 by Citigroup
Charles River Labs Raised to Neutral From Sell by Citigroup
Charles River Analyst Ratings